Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus ENLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus ENLON.
ADLARITY vs ENLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, inhibiting neuromuscular transmission.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
Intravenous: 0.1 mg/kg followed by 1-2 mg/min infusion for reversal of neuromuscular blockade; adjust based on twitch response.
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
Terminal elimination half-life of 1.5-2.5 hours; prolonged in renal impairment and elderly patients
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
Primarily renal excretion of unchanged drug (85-95%), with minor fecal elimination (<5%)
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor